All the countries of the world are busy preparing to win the fight against the epidemic (Covid-19 Pandemic). The coronavirus vaccine is being searched around the world. Trials are nearing completion in many countries. Rapid action is being taken to deliver the vaccine to its final stage. Especially in European countries, given the second wave of corona, vaccination will be needed soon. According to the World Health Organization (WHO), the corona vaccine is currently being tested by 33 companies, 9 of which are in the third phase of clinical trials.
The Oxford University and AstraZeneca vaccines, which were at the forefront of the vaccine race, are now lagging behind. After closing the trial in many countries, it will now take a little longer to reach the end. So, the American Modern vaccine and the Bioentech-Pfizer vaccine are also included in this race. Many companies have claimed to have launched the vaccine by the end of this year or early next year.
The vaccine may hit the market by November
According to media reports, the BioNTech & Pfizer vaccine has taken the lead in the race. It is expected that both the companies will evaluate the effects of the vaccine by October and then the vaccine can be introduced in the market by November if approved for use in emergencies. Recently, Ugur Sahin, CEO and co-founder of Bioentech, said his vaccine could arrive by the end of October.
The American vaccine is expected to arrive in December
The third phase of the American company Modern’s vaccine is currently in trial. He is also being considered ahead in the vaccine race. It is expected that the company will learn about the effects of the vaccine in December. It is expected to hit the market by the end of December or early next year.
Why the Oxford vaccine was left behind?
In fact, Oxford’s trial was recently suspended because someone fell ill during the trial. However, it was later discovered that he had not fallen ill due to the vaccine, after which the trial of the vaccine was resumed. However, trials have not yet resumed in some countries, which is why the vaccine will be available in the market next year.
China’s vaccine by the end of the year
China’s Synovac Biotech Pharma may launch the vaccine by the end of this year. Another Chinese company, Casino Biologics Inc. The Ad5-nCoV vaccine is also expected to hit the market by the end of this year. The vaccine is being developed in collaboration with the Beijing Institute of Biotechnology. However, the third phase of the trial of both vaccines is currently underway.